

[View this email in your browser](#)

Randomized Trial to Prevent Vascular Events in HIV



The REPRIEVE Leadership Team would like to wish all of you a very happy holiday season and a prosperous New Year! As we approach the end of 2019, we would like to take a moment to reflect on some of the great accomplishments we have made together in the last year.

2019 IN REVIEW

- Completed enrollment of REPRIEVE (A5332) in March 2019, with 7557 participants from 11 countries, making REPRIEVE the largest ACTG study and largest randomized placebo-controlled clinical trial in HIV to date.
- Through collaboration with colleagues in the EU, REPRIEVE (EU5332) successfully launched and completed enrollment of 213 participants.
- Over 200 REPRIEVE Investigators and staff attended REPRIEVE meetings at the ACTG Annual Network Meeting and CROI 2019.
- REPRIEVE Co-Investigator, Dr. Carl Fichtenbaum, wrote and performed an *original song* at CROI 2019! What was the subject? REPRIEVE, of course!
- NIH Leadership, including Dr. Gary Gibbons and Dr. Anthony Fauci, recognized REPRIEVE teams and participants in a [thank you video](#).
- Manuscripts focusing on the design and rationale for REPRIEVE and the Mechanistic Substudy were published in the American Heart Journal.

We could not have accomplished all of this without your hard work and dedication! We are looking forward to continuing our work together in the New Year!

Please note, holidays will impact the following:

- BRI will be closed on Wednesday, December 25th and Wednesday, January 1st. Please do not ship during the 4th week of December or the 1st week of January. If your site is scheduled to ship during this time, please contact brirepository@afbr-bri.com to make alternate shipping arrangements.
- Frontier Science will be closed and no user support assistance will be available on Wednesday, December 25th or Wednesday, January 1st. If you have any questions, please contact user support by email at user.support@fstrf.org.
- For sites participating in A5333s: PaxGene tube requests must be made by Wednesday, December 18th. Requests made after December 18th will be responded to on Monday, January 6th. PaxGene tube requests can be made by emailing reprievesupplies@partners.org.

We Need Your Input!

REPRIEVE has been successful thanks to the incredible commitment of our 7500+ participants. In recognition of their continued engagement, *we want to thank participants with a REPRIEVE Keepsake*. These keepsakes would be distributed to sites by the REPRIEVE CCC, in turn, sites would distribute them to participants when a participant reaches a study milestone.

To help the CCC determine what would be most appreciated, [CLICK HERE](#) to complete this 3 question survey

Did you know that some ACTG website domains have changed?

In case you missed the email see below regarding what's old and what's new...

Website	Old URL	NEW URL
ACTG Member Website	https://member.actgnetwork.org	https://member.mis.s-3.com
ACTG Portal Website	https://portal.actgnetwork.org	https://portal.mis.s-3.com
ACTG Proposal Submission Website	https://submit.actgnetwork.org	https://submit.mis.s-3.com
ACTG Support Website	https://support.actgnetwork.org	https://support.mis.s-3.com

As of Wednesday, November 27th, the 'actgnetwork.org' based addresses above no longer function. Please be advised to update all bookmarks as noted above, and to use the new addresses when entering them manually. Pre-existing links included in emails will also no longer work. They may be manually updated to the new address indicated above, or you may contact the associated ACTG Network Coordinating Center representative if you require additional assistance.


Please Note: The Public website - <https://actgnetwork.org> - was not changed in this process.

If you have any questions or concerns, please direct them to Larry Lawrence at llawrence@s-3.com.



Recognize your REPRIEVE participants this holiday season!

Small tokens of appreciation or acts of kindness can go a long way, especially during the holidays. Take a moment to use the REPRIEVE thank you cards to write a note to your participants, or simply give them a quick call, and wish them a safe and happy holiday season and thank them for all they have done for REPRIEVE this year!



A note from the REPRIEVE Lab Committee

Before shipping to BRI, don't forget to do a QA/QC of every single aliquot to ensure that *EVERY* label is clearly printed AND legible!

Illegible labels is a very common issue we see on shipment evaluations reported from BRI. Ensuring that all labels are clearly printed BEFORE shipping to BRI will prevent you from having to reprint and resend new labels to BRI.

Next REPRIEVE DSMB Meeting is December 16th, 2019

At this time, all outstanding queries should be resolved. We look forward to sharing updates from the meeting with you in the new year.

Timeline for DSMB Meeting Dec 16th


Task		Deadline* (2019)
Sites	All data for visits through Oct 4 entered	Oct 21 (Monday)
Sites	All adjudication packets for potential MACE events by Oct 4 with work-up complete submitted to DCC (MGH)**	Oct 25 (Friday)
Sites	All outstanding queries resolved	Nov 8 (Friday)
Sites	Respond to last minute outstanding queries	Nov 22 (Friday)
All	DSMB Meeting	Dec 16 (Monday)

*Deadlines are Close of Business on the given date unless otherwise noted

** Please ensure that you have responded to all queries and clarifications from the DCC regarding source documents submitted for potential adjudicated events. This will ensure that the DCC is able to submit complete packets to TIMI for adjudication prior to the DSMB.

Have you sent us your REPRIEVE team photo?

We would like to feature sites on our website and on future newsletters! Please send a team photo and retention or heart healthy tip to reprieve.news@fstrf.org to be featured!



Save the Date!
Tuesday, January 21st, 2019
1:00 – 2:00 PM ET

For the next Monthly Site Call!

If you missed the November monthly site call, [click here](#) to download slides.

REPRIEVE (A5332): Are you up to date?

For A5332 please use:

Protocol Version 5.0 dated 04/01/2019

MOPS Version 5.0 dated 11/29/2019 (updated!)

A5332 LPC for ACTG Sites Version 5.0 dated 04/11/2019

A5332 LPC for Non-ACTG Sites Version 5.0 dated 04/11/2019

These documents are on the [A5332 PSWP](#)

Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use

Protocol Version 5.0 dated 04/01/2019

MOPS Version 4.0 dated 04/10/2018

A5333s LPC Version 4.0 dated 03/23/2018

These documents are on the [A5333s PSWP](#)

For future reference, all newsletters are available on the [REPRIEVE Website](#).

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at reprieve.news@fstrf.org



REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital
55 Fruit Street, 5LON 207
Boston, MA USA 02144

Our mailing address is:

reprieve.news@fstrf.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

